In Vitro Activities of 21 Antimicrobial Agents Alone and in Combination with Aminoglycosides or Fluoroquinolones against Extended-Spectrum-β-Lactamase-Producing Escherichia coli Isolates Causing Bacteremia

Documenti analoghi

• Clinical and Molecular Epidemiology of Community-Onset Bacteremia Caused by Extended-Spectrum β-Lactamase-Producing Escherichia coli over a 6-Year Period
  di: Kang, Cheol-In, et al.
  Pubblicazione: (2013)
• Characteristics and Clinical Outcomes of Extended-Spectrum beta-lactamase-producing Klebsiella pneumoniae Bacteremia in Cancer Patients
  di: Nham, Eliel, et al.
  Pubblicazione: (2020)
• Epidemiology of Ciprofloxacin Resistance and Its Relationship to Extended-Spectrum β-Lactamase Production in Proteus mirabilis Bacteremia
  di: Sohn, Kyung Mok, et al.
  Pubblicazione: (2011)
• Breakthrough Bacteremia Due to Extended-Spectrum-β-Lactamase-Producing Klebsiella pneumoniae during Combination Therapy with Colistin and Tigecycline
  di: Cho, Sun Young, et al.
  Pubblicazione: (2012)
• Failure of Ciprofloxacin Therapy in the Treatment of Community-Acquired Acute Pyelonephritis caused by In-Vitro Susceptible Escherichia coli Strain Producing CTX-Type Extended-Spectrum β-Lactamase
  di: Seok, Hyeri, et al.
  Pubblicazione: (2018)